REGN Today - Aug 09: Combo Drug Falls Short

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

REGN Today - Aug 09: Combo Drug Falls Short

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey, your friendly investor buddy, here to break down what went down with Regeneron Pharmaceuticals today. So, REGN had a bit of a green day, up about one and a half percent. Not too shabby!

Now, here’s the scoop. Regeneron’s stock had a pretty solid day overall, but there’s some drama behind the scenes. The big news? Their combo drug didn’t quite stack up against Merck’s Keytruda in a melanoma trial. Yeah, that one stung a bit, especially since investors had their hopes up for that one. When news like that drops, people tend to hit the sell button fast, but surprisingly, the stock held its ground pretty well.

On the flip side, there’s some positive buzz around Regeneron keeping their buybacks and dividends in focus. It looks like they’re staying committed to returning value to shareholders, which is always nice to see. But that melanoma trial overshadowed a lot of the good vibes today.

In terms of buying and selling, there were some interesting moves too. Beacon Investment Advisory sold a chunk of shares, while PensionDanmark decided to scoop up a few more. It’s like a little dance of buying and selling going on.

One thing to keep an eye on is how they’re planning to navigate the fallout from that trial. They’re still in the game with other drugs and treatments, but that setback might make investors a bit jittery for a while.

So, to wrap it up, Regeneron had a mixed bag today. A little bump up in price, but some serious news that could shake things up. Just remember, this is all for your info and entertainment. Always do your own homework before making any moves. Catch you later!

まだレビューはありません